Atelerix, a biotechnology company specializing in cell preservation, has partnered with Rodon Global, an international freight company serving the clinical trials and drug discovery sectors. The agreement will integrate Atelerix’s non-cryogenic preservation technology into Rodon’s logistics network.
This collaboration aims to improve the shipping and storage of temperature-sensitive biomaterials, offering a solution that avoids the need for freezing. Rodon will offer Atelerix’s hypothermic preservation solutions to its clients, expanding the reach of Atelerix’s technology.
The partnership will provide new options for enhancing efficiency in biomedical research and therapeutic development. For Atelerix, the agreement provides access to a substantial new customer base. Simultaneously, Rodon gains a unique service offering to address challenges in cold-chain logistics.
Atelerix’s patented hydrogel technology stabilizes cell membranes and preserves biological function during transport at ambient temperatures for up to two weeks. This reduces waste, energy consumption, and simplifies handling. The technology is suitable for various biomaterials, including blood, cells, tissues, and viruses.
Alastair Carrington, CEO of Atelerix, noted the growing global demand for efficient biological substance transport and storage solutions. He highlighted the partnership’s potential to expand Atelerix’s presence in the South African life science sector and beyond. The companies will showcase their collaboration at the South African Clinical Research Association (SACRA) conference in Pretoria in October.
Leonard Neil Lazarus, CEO of Rodon Global, emphasized the transformative potential of Atelerix’s technology in addressing supply chain challenges related to temperature-sensitive materials within drug discovery and clinical research. He described the partnership as a significant milestone for Rodon, enabling the company to expand its services and better support its life science clients.
This partnership follows Atelerix’s recent exclusive distribution agreement with MineBio in China, further expanding its global reach. The company is committed to providing a cost-effective, cryo-free transport solution worldwide. The technology has particular applications in cell and gene therapy manufacturing. Rodon Global’s extensive international network will be instrumental in distributing Atelerix’s innovative preservation solutions.
Related
